BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19706697)

  • 1. Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.
    Robles O; Zabala A; Bombín I; Parellada M; Moreno D; Ruiz-Sancho A; Arango C
    Schizophr Bull; 2011 Mar; 37(2):405-15. PubMed ID: 19706697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine compared to quetiapine in adolescents with a first psychotic episode.
    Arango C; Robles O; Parellada M; Fraguas D; Ruiz-Sancho A; Medina O; Zabala A; Bombín I; Moreno D
    Eur Child Adolesc Psychiatry; 2009 Jul; 18(7):418-28. PubMed ID: 19198920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
    Vigen CL; Mack WJ; Keefe RS; Sano M; Sultzer DL; Stroup TS; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Tariot PN; Zheng L; Schneider LS
    Am J Psychiatry; 2011 Aug; 168(8):831-9. PubMed ID: 21572163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
    Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
    Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.
    Riedel M; Müller N; Spellmann I; Engel RR; Musil R; Valdevit R; Dehning S; Douhet A; Cerovecki A; Strassnig M; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Oct; 257(7):402-12. PubMed ID: 17629725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.
    Goldberg TE; Burdick KE; McCormack J; Napolitano B; Patel RC; Sevy SM; Goldman R; Lencz T; Malhotra AK; Kane JM; Robinson DG
    Schizophr Res; 2009 Feb; 107(2-3):262-6. PubMed ID: 19042105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
    Volavka J; Czobor P; Derks EM; Bitter I; Libiger J; Kahn RS; Fleischhacker WW;
    J Clin Psychiatry; 2011 Jul; 72(7):955-61. PubMed ID: 21824456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.
    Urben S; Baumann P; Barcellona S; Hafil M; Preuss U; Peter-Favre C; Clarke S; Halfon O; Holzer L
    Psychiatr Q; 2012 Sep; 83(3):311-24. PubMed ID: 22101738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial.
    Johnsen E; Jørgensen HA; Kroken RA; Løberg EM
    Eur Psychiatry; 2013 Mar; 28(3):174-84. PubMed ID: 22153730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
    Frazier JA; Giuliano AJ; Johnson JL; Yakutis L; Youngstrom EA; Breiger D; Sikich L; Findling RL; McClellan J; Hamer RM; Vitiello B; Lieberman JA; Hooper SR
    J Am Acad Child Adolesc Psychiatry; 2012 May; 51(5):496-505. PubMed ID: 22525956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
    Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
    Fraguas D; Merchán-Naranjo J; Laita P; Parellada M; Moreno D; Ruiz-Sancho A; Cifuentes A; Giráldez M; Arango C
    J Clin Psychiatry; 2008 Jul; 69(7):1166-75. PubMed ID: 18588363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.